CompanySMMTNasdaqMiami, FL

Summit Therapeutics

Summit Therapeutics develops ivonescimab, a bispecific antibody combining PD-1 blockade with anti-VEGF activity for oncology indications.

SEC EDGAR ClinicalTrials.gov smmttx.com

6-KSep 30Latest SEC filing

Sep 29Latest story

September 2026

HUTCHMED, AstraZeneca file US NDA for Orpathys plus Tagrisso in MET-driven lung cancer

Sep 29Regulatory decisionAstraZeneca Hutchmed

Summit reports updated HARMONi overall survival data at WCLC 2026

Sep 15Clinical readoutivonescimab Summit Therapeutics

Summit Therapeutics registers Phase 2/3 HARMONi-GU1 trial in urothelial carcinoma

Sep 11Trial updateivonescimab Summit Therapeutics

August 2026

Summit's partner Akeso reports positive Phase III data for ivonescimab in bile duct cancer

Aug 26Clinical readoutivonescimab Summit Therapeutics

MD Anderson registers Phase II trial of Summit's ivonescimab in rare appendix cancer

Aug 10Trial updateivonescimab Summit Therapeutics

Summit Therapeutics starts Phase II/III bladder cancer trial for ivonescimab

Aug 5Clinical readoutivonescimab Summit Therapeutics

MD Anderson registers Phase 2 trial of Summit's ivonescimab in rare adrenal cancers

Aug 3Trial updateivonescimab Summit Therapeutics

July 2026

Summit reports Q2 2026 results as HARMONi OS data hold up in western patients

Jul 23Clinical readoutGlaxoSmithKline ivonescimab

Summit Therapeutics discloses going concern doubt alongside $380 million stock offering

Jul 23Financingivonescimab Summit Therapeutics

Summit Therapeutics sets up $380 million at-the-market stock sale program

Jul 23PartnershipSummit Therapeutics